AT1 FY21 - General Discussion + FA, page-523

The sales agreement with AccessBio is "take or pay", we've effectively already sold those 2M units regardless of whether they receive FDA approval. From memory that agreement can be expanded upon once FDA approval is received but the first part is done, in our favour. Payment is expected sometime in 2021, will come earlier in the year with approval.

By the end of 2021 we'll be supplying the US, India and Europe. Market cap should be multiples from here and anybody positioned now will have a CGT discount as reward for their patience. Can't honestly see anybody losing money from these levels, only from opportunity cost from the current/pending resources boom.

GLTAH and Happy New Year, see you all again in 2021!